Aroa Biosurgery share price jumps 8% on approvals

The Aroa Biosurgrey share price has jumped 8% following the company's announcement the FDA and European Union approved two of its products.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Aroa Biosurgery Ltd (ASX: ARX) share price has closed 7.69% higher today after announcing it has secured United States Food and Drug Administration (FDA) clearance for one of its products, 'Symphony'. In addition, the company received European approval for its product, 'Myriad', and released an investor presentation today.

The New Zealand-based Aroa is a soft tissue regeneration company focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. 

Symphony FDA clearance

Symphony is designed to reduce complex wound healing time in the proliferative phase where normal healing is impaired due to disease.

Its pending commercial launch in 2021 presents a major expansion in Aroa's product portfolio in the US. Pleasingly, the launch will take the company's addressable market to more than $2.5 billion, up from $1.5 billion previously.

Aroa CEO Brian Ward said "Symphony will give clinicians a new option to treat some of their most hard to heal patients, in what we estimate is a US market size of US$1.15 billion for the product".

European approval for Myriad

Aroa's product, Myriad, has received the 'CE mark' to allow commercialisation in the European Union. Myriad supports rapid tissue growth for dermal tissue reconstruction. The company expects the launch of the product to occur in 2021. 

The FDA clearance in June 2017 led to first sales earlier this year. Additionally, it is estimated the total addressable market size for the product globally is US$350 million.

July investor presentation

According to its investor presentation, all Aroa's products are based on its proprietary Endoform platform technology which is a unique Extracullular Matrix (ECM) derived from sheep forestomach.

Additionally, the company says its technology offers superior regenerative performance at a significantly lower cost than other biologics enabling more patients to have access to the benefits of regenerative healing.

The company's products have competitor protection due to the patents it owns. This includes 10 patents and 25 pending patent applications across 6 patent families. Aroa has 5 patented products selling across the US alone.

Pleasingly, the company's revenue has grown from $8.43 million in FY18 to $21.92 million in FY20. Furthermore, its product gross margin of 71% in FY20 has expanded compared to 36% in FY18. It is earnings before tax, depreciation and amortisation (EBITDA) positive in FY20 on a proforma basis.

Aroa Biosurgery share price performance

The Aroa Biosurgery share price closed today's trade at $1.54 which represents a 14.07% increase since it listed on the ASX just last Friday.

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Three miners stand together at a mine site studying documents with equipment in the background
Materials Shares

BHP share price on watch after Anglo American takeover update

BHP is seeking an extension to its deadline to get a deal over the line.

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was carnage on the ASX this hump day.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Cheap Shares

How I'd try to turn an empty portfolio into $300k by buying cheap ASX shares, starting now

If I was looking for cheap ASX shares today, here's what I'd buy.

Read more »

Young couple having pizza on lunch break at workplace.
Broker Notes

Domino's share price is set to soar 22%, say top brokers

Serving up another positive view for the pizza giant.

Read more »

Investor sitting in front of multiple screens watching share prices
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Share Gainers

Why Alligator Energy, Data#3, Fisher & Paykel, and IPD shares are storming higher

These shares are avoiding the market selloff on Wednesday. But why?

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Cettire, Neuren, Peter Warren, and Qantas shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A goldfish jumps out of a crowded fishbowl into another empty bowl, indicating an ASX market leader with a strong share price
Healthcare Shares

Up 20% in 2024, why this ASX 200 healthcare stock just hit a new 52-week high

This healthcare stock has been on fire over 2024.

Read more »